Sub-cellular specific targeting of JNK as a novel anti-metastatic therapy for triple negative breast cancer

"We now propose that targeting specific vulnerabilities within these networks will allow us to develop the next generation of cancer drugs that can finally stop JNK from promoting the growth of metastases in triple negative breast cancer patients without stopping the good things that it does elsewhere in the body."

- The Garvan Institute Of Medical Research